Clinicopathologic and Molecular Characterization of Low-Grade, Early-Stage, and HER2-Positive Invasive Breast Carcinoma
Publication: American Journal of Clinical Pathology, 2025, Vol. 163, No. Read More
Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes
Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Read More
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among Read More
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Publication: ESMO Annals of Oncology, Breast cancer, early stage, Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read More
ASCO 2020: HER2 Reclassification
PUBLICATION: ASCO 2020 AUTHORS: Adam Brufsky, Jennifer A. Crozier, Paul Read More
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test
PUBLICATION: Translational Oncology Volume 13, Issue 4, April 2020, 100756 Read More
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More
